Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
161. |
ECCT/22/03/10 | Solidarity Trial Vaccines Solidarity Trial Vaccines: An international randomised trial of candidate vaccines against COVID-19 |
Principal Investigator(s) 1. Ayallo, John Mark O, AYALLO 2. Prof KAWANGO AGOT AGOT 3. DR. LUCAS TINA OTIENO OTIENO 4. DR.MARICIANA ONONO ONONO 5. DR.JANET OYIEKO OYIEKO 6. DR.Fredrick Kipyego Sawe SAWE 7. DR. MICHAEL M MUTUA Mutua 8. Dr Joshua Kimani KIMANI 9. DR. IRENE A. MUGENYA MUGENYA Site(s) in Kenya 1. SWOP (Nairobi City county) 2. K-IRDO –KISUMU (Kisumu county) 3. VIBRI- VICTORIA BIOMEDICAL RESEARCH INSTITUTE –KISUMU (Kisumu county) 4. KEMRI-CENTRE FOR MICROBIOLOGY RESEARCH (CMR) LUMUMBA –KISUMU (Kisumu county) 5. KEMRI –CENTRE FOR CLINICAL RESEARCH BUTERE(CCR) (Kakamega county) 6. Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) (Kericho county) 7. UNIVERSITY OF NAIROBI- KAVI- KANGEMI (Nairobi City county) 8. UNIVERSITY OF NAIROBI- KAVI- KNH (Nairobi City county) |
View |
162. |
ECCT/22/03/08 | CVIA 092 “ A Phase 3 Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Safety (Ages 6 Months to 45 Years) and Non-inferiority (Ages 9-12 Months) of Multi-dose and Single-dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) against Typbar TCV® and Lot-to-Lot Consistency of the Immune Response (Ages 9-12 Months) to Multi-dose Vial Formulation EuTCV in Healthy African Participants”. |
Principal Investigator(s) 1. Dr Lucy Koech Chepkurui Koech Site(s) in Kenya KEMRI/ KERICHO CRC |
View |
163. |
ECCT/22/03/06 | Sickle Cell Disease A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Janet Oyieko 2. Fredrick Chite Asirwa 3. Bernhards Ogutu Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research institute (Kisumu county) 3. International Cancer Centre (Uasin Gishu county) 4. CREATES - Strathmore University Medical Centre (Nairobi City county) |
View |
164. |
ECCT/22/03/03 | HVTN 140/HPTN 101 A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants_HVTN 140/HPTN 101 |
Principal Investigator(s) 1. Josphat kosgei Site(s) in Kenya KEMRI WRP, KERICHO |
View |
165. |
ECCT/22/03/04 | VIBRI COVID-19-001/2021 A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda). |
Principal Investigator(s) 1. Dr. Lucas Otieno Tina Site(s) in Kenya Victoria Biomedical Research Institute, |
View |